Linagliptin/Metformin Hcl Pharos

Linagliptin/Metformin hydrochloride, the active ingredient in Linagliptin/Metformin Hcl Pharos, is a DPP‑4 inhibitor and biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults, helping to lower blood glucose when combined with diet and exercise. GNH USA supplies Linagliptin/Metformin Hcl Pharos as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin/Metformin is indicated for type 2 diabetes mellitus, acting on the glucose regulation pathway to improve glycemic control. - Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels. - Type 2 diabetes mellitus (combination therapy): enhances overall glycemic control when added to other oral antidiabetics. - Type 2 diabetes mellitus (adjunct to lifestyle): supports diet and exercise interventions to achieve target HbA1c.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, usually transient. - Headache: mild tension‑type pain. - Dizziness: light‑headed sensation, especially on standing.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatic failure: jaundice, abnormal liver tests.

Before initiating therapy, consider the following precautions: - Renal function assessment: evaluate eGFR and adjust use if severely impaired. - Liver disease monitoring: check hepatic enzymes periodically. - Risk of hypoglycemia: avoid or adjust dose when combined with insulin or sulfonylureas. - Pregnancy and lactation: use only if benefits outweigh potential risks. - Store at ambient temperature: keep below 25 °C in the original pack, protect from moisture and heat.

Linagliptin/Metformin may interact with several medicines. Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycemia. - Radiographic contrast agents: may precipitate metformin‑associated lactic acidosis. - Other DPP‑4 inhibitors: additive pharmacologic effect, not recommended.

Moderate Interactions (Monitor Closely): - Diuretics affecting renal function: monitor eGFR. - ACE inhibitors/ARBs: watch renal function and potassium levels. - Beta‑blockers: may mask hypoglycemia symptoms. - Corticosteroids: may raise glucose, requiring dose adjustment.